BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71
18 results:

  • 1. myl-1402O: A Bevacizumab Biosimilar.
    Lee A
    Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity.
    Li F; Sun Q; Liu K; Zhang L; Lin N; You K; Liu M; Kon N; Tian F; Mao Z; Li T; Tong T; Qin J; Gu W; Li D; Zhao W
    Nat Commun; 2020 Aug; 11(1):4184. PubMed ID: 32826889
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.
    Liu SB; Lin XP; Xu Y; Shen ZF; Pan WW
    J Ovarian Res; 2018 Oct; 11(1):90. PubMed ID: 30336783
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. pml-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human ovarian cancers.
    Gentric G; Kieffer Y; Mieulet V; Goundiam O; Bonneau C; Nemati F; Hurbain I; Raposo G; Popova T; Stern MH; Lallemand-Breitenbach V; Müller S; Cañeque T; Rodriguez R; Vincent-Salomon A; de Thé H; Rossignol R; Mechta-Grigoriou F
    Cell Metab; 2019 Jan; 29(1):156-173.e10. PubMed ID: 30244973
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Chromatin-Remodeling Factor SPOC1 Acts as a Cellular Restriction Factor against Human Cytomegalovirus by Repressing the Major Immediate Early Promoter.
    Reichel A; Stilp AC; Scherer M; Reuter N; Lukassen S; Kasmapour B; Schreiner S; Cicin-Sain L; Winterpacht A; Stamminger T
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743358
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Diagnostic Accuracy and Optimal Cutoff Value of Serum HE4 to Predict ovarian cancer in Thai Women with Pelvic Masses.
    Yanaranop M; Tiyayon J; Nakrangsee S; Thinkhamrop B
    J Med Assoc Thai; 2016 Dec; 99(12):1263-71. PubMed ID: 29952496
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report.
    Anastasi E; Porpora MG; Pecorella I; Bernardo S; Frati L; Benedetti Panici P; Manganaro L
    Tumour Biol; 2014 Jul; 35(7):6969-71. PubMed ID: 24740561
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
    Singh S; Pradhan AK; Chakraborty S
    Biochim Biophys Acta; 2013 Oct; 1833(10):2357-68. PubMed ID: 23770046
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. DAXX silencing suppresses mouse ovarian surface epithelial cell growth by inducing senescence and DNA damage.
    Pan WW; Yi FP; Cao LX; Liu XM; Shen ZF; Bu YQ; Xu Y; Fan HY; Song FZ
    Gene; 2013 Sep; 526(2):287-94. PubMed ID: 23542781
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.
    Pan WW; Zhou JJ; Liu XM; Xu Y; Guo LJ; Yu C; Shi QH; Fan HY
    J Biol Chem; 2013 May; 288(19):13620-30. PubMed ID: 23539629
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. EVI1 splice variants modulate functional responses in ovarian cancer cells.
    Dutta P; Bui T; Bauckman KA; Keyomarsi K; Mills GB; Nanjundan M
    Mol Oncol; 2013 Jun; 7(3):647-68. PubMed ID: 23517670
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Influence of perioperative oxygen fraction on pulmonary function after abdominal surgery: a randomized controlled trial.
    Staehr AK; Meyhoff CS; Henneberg SW; Christensen PL; Rasmussen LS
    BMC Res Notes; 2012 Jul; 5():383. PubMed ID: 22840231
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. SnoN/SkiL, a TGFβ signaling mediator: a participant in autophagy induced by arsenic trioxide.
    Raffoul F; Campla C; Nanjundan M
    Autophagy; 2010 Oct; 6(7):955-7. PubMed ID: 20699661
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice.
    Engler H; Machemer TR; Schluep T; Wen SF; Quijano E; Wills KN; Harper AE; Maneval DC; Conroy SE
    Mol Ther; 2003 Apr; 7(4):558-64. PubMed ID: 12727120
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.
    Pulsoni A; Pagano L; Lo Coco F; Avvisati G; Mele L; Di Bona E; Invernizzi R; Leoni F; Marmont F; Mele A; Melillo L; Nosari AM; Pogliani EM; Vignetti M; Visani G; Zagonel V; Leone G; Mandelli F
    Blood; 2002 Sep; 100(6):1972-6. PubMed ID: 12200354
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
    Cohen MH; Hirschfeld S; Flamm Honig S; Ibrahim A; Johnson JR; O'Leary JJ; White RM; Williams GA; Pazdur R
    Oncologist; 2001; 6(1):4-11. PubMed ID: 11161223
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. ALT-associated pml bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
    Grobelny JV; Godwin AK; Broccoli D
    J Cell Sci; 2000 Dec; 113 Pt 24():4577-85. PubMed ID: 11082050
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Topotecan and pml: the limits of pharmaceutical industry research.
    Learned J
    Notes Undergr; 1996 Sep; (No 33):1-3. PubMed ID: 11363913
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.